Abstract
Review of literature and own studies on the pharmacology and clinical pharmacology of the domestic -adrenergic blocker pyrroxan (INN: proroxane). The drug was developed in the 1970s at the Institute of Toxicology of the USSR Ministry of Health (Leningrad). Expectations from -blockers created during this period (phenoxybenzamine, phentolamine, tropafen, fepracet, dihydrogenated ergot alkaloids) were high, especially in terms of the treatment of hypertensive and ischemic conditions, however, only few drugs from this group were used in clinical practice for these purposes (prazosin, doxazosin and some others). For pyrroxan, this direction was not the main one, and it was positioned as a means of treating diencephalic disorders like vegetative crises, where the drug immediately gained popularity, and this direction of use was clearly fixed to it. In the same period, the anti-alcohol and anti-drug action of -adrenergic blockers was found, since both in the experiment and in the clinic they demonstrated the suppression of alcohol (drug) motivation and a decrease in alcohol and drug consumption. Thelatter served as an impetus to the use of pyrroxane mainly in psychiatry, narcology and, to a lesser extent, in neurology, and recently the drug has been positioned almost exclusively for use in these areas of medicine. Thearticle analyzes the current clinical use of pyrroxane.